Navigation Links
First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries

hieved their LDL-C goal utilizing the 20mg dose of CRESTOR.

-Ends-
25 March 2007

Media enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065

Notes To Editors
* People at low-risk of coronary heart disease as described in the METEOR study had a Framingham 10- year risk of less than 10 percent. The Framingham risk score is a method to determine an individual's risk of having either a fatal or non-fatal heart attack over the following 10 years. The risk score is based on an
individual's cholesterol level, blood pressure, smoking status, age and gender.

ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden) was a 104-week, open label, single-arm, blinded endpoint study designed to study the effect of CRESTOR 40mg in 507 patients who had undergone coronary angiography and who had evidence of coronary artery disease (CAD).
Key findings from ASTEROID include:

CRESTOR brought about a 0.79 per cent (median) reduction in percent atheroma volume in the entire target vessel (p<0.001) – first primary endpoint
CRESTOR brought about a 9.1 per cent (median) reduction in total atheroma volume in the most diseased 10mm segment of the target vessel (p<0.001) – second primary endpoint
CRESTOR brought about a 6.8 per cent (median) reduction in total atheroma volume in the entire target vessel (p<0.001) – secondary endpoint
These changes were associated with a 53 per cent reduction in LDL-C (p<0.001) and a 15% increase in HDL-C (p<0.001)
ORION (Outcome of Rosuvastatin Treatment on Carotid Artery Atheroma: a Magnetic Resonance Imaging ObservatioN) was the first study to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... , WARSAW, Ind., Nov. 24 ... today it will be participating in the 21st Annual Piper Jaffray ... 2009, at 8:00 a.m. Eastern Time. , A live ... website at http://investor.zimmer.com . The webcast will be archived ...
... , CARLSBAD, Calif., Nov. 24 Isis Pharmaceuticals, Inc. (Nasdaq: ... will present a company overview at Piper Jaffray,s 21st Annual Health ... at The New York Palace Hotel. , A live audio webcast ... section of the Company,s Web site, www.isispharm.com . A ...
Cached Medicine Technology:
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... ... ... Tony Rico has recently been promoted to Senior Vice President of Operations at Jackson ... 1, 2009. , , , , ,"This position has been vacant for a ...
... On Tuesday, October 20, 2009, at 1:00 PM Eastern Time/10:00 AM ... (Nasdaq and MTA: CTIC) management team will host an Annual Meeting of ... WA 98119. The meeting will also be webcast live on CTI,s website ... ...
... being stifled by a U.S. law and successful patent challenges ... this week,s issue of the journal Science . ... of Management at the Georgia Institute of Technology, argue in ... challenges -- a provision of the Hatch-Waxman Act of 1984 ...
... After the Austin City Limits music festival concluded, spa ... Austin, Tx. for the 19th annual International SPA Association ... spa community, participated in educational sessions, learned about the ... The Conference theme, "Simplify," resonated with attendees as ...
... National Awareness Campaign to Combat Breast Cancer has been ... Awareness month. The campaign is led by Princess Hessah bint Trad ... wife of the Custodian of the Two Holy Mosques ... bin Abdulaziz. It officially launched on October 10. , As ...
... scientists interested in finance, entrepreneurships and the chemical sciences are ... Medium Business Webinar for an opportunity to learn about trends ... Scheduled for Thursday, Oct. 22, 2 3 p.m. ... of International eChem and author of the well-regarded ICIS "Chemicals ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 2Health News:Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest 3Health News:2009 ISPA Conference & Expo Rocks Out With Lance Armstrong in Austin 2
... An APTT-based assay for the detection ... poor anticoagulant response to activated protein C ... an estimation of the anticoagulant function in ... risk associated with inherited and acquired APC ...
Inquire...
Each Uro-Safe® vinyl leg bag is hand-tested for defects through each phase of the manufacturing process and packaged individually in a sterile, easy, peel-open pouch with two latex leg straps....
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: